ATE484585T1 - Anti-myosin-va-sirna und depigmentierung der haut - Google Patents

Anti-myosin-va-sirna und depigmentierung der haut

Info

Publication number
ATE484585T1
ATE484585T1 AT06830566T AT06830566T ATE484585T1 AT E484585 T1 ATE484585 T1 AT E484585T1 AT 06830566 T AT06830566 T AT 06830566T AT 06830566 T AT06830566 T AT 06830566T AT E484585 T1 ATE484585 T1 AT E484585T1
Authority
AT
Austria
Prior art keywords
sirna
myosin
sense rna
rna strand
depigmentation
Prior art date
Application number
AT06830566T
Other languages
English (en)
Inventor
Anne-Marie Schmitt-Milas
Jo Lambert
Wendy Westbroek
Gele Mireille Van
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Application granted granted Critical
Publication of ATE484585T1 publication Critical patent/ATE484585T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06830566T 2005-12-12 2006-12-12 Anti-myosin-va-sirna und depigmentierung der haut ATE484585T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512553A FR2894582B1 (fr) 2005-12-12 2005-12-12 Sirna anti myosine va et depigmentation de la peau
PCT/EP2006/069618 WO2007068704A1 (fr) 2005-12-12 2006-12-12 Sirna anti myosine va et depigmentation de la peau

Publications (1)

Publication Number Publication Date
ATE484585T1 true ATE484585T1 (de) 2010-10-15

Family

ID=36617133

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830566T ATE484585T1 (de) 2005-12-12 2006-12-12 Anti-myosin-va-sirna und depigmentierung der haut

Country Status (23)

Country Link
US (1) US7999096B2 (de)
EP (2) EP1963507B1 (de)
JP (1) JP2009518022A (de)
KR (1) KR20080079298A (de)
CN (1) CN101326286A (de)
AT (1) ATE484585T1 (de)
AU (1) AU2006325359A1 (de)
BR (1) BRPI0619738A2 (de)
CA (1) CA2632837A1 (de)
DE (1) DE602006017586D1 (de)
DK (1) DK1963507T3 (de)
ES (1) ES2351996T3 (de)
FR (1) FR2894582B1 (de)
HR (1) HRP20100666T1 (de)
IL (1) IL191728A0 (de)
MA (1) MA30034B1 (de)
NO (1) NO20083089L (de)
PL (1) PL1963507T3 (de)
PT (1) PT1963507E (de)
RU (1) RU2008125041A (de)
TN (1) TNSN08252A1 (de)
WO (1) WO2007068704A1 (de)
ZA (1) ZA200805739B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4981381B2 (ja) * 2006-08-04 2012-07-18 株式会社ナリス化粧品 美白用皮膚外用剤
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
JP5420669B2 (ja) * 2008-09-10 2014-02-19 エル、ベ、エム、アッシュ、ルシェルシュ 皮膚または毛髪の色素沈着の検討または調節に有用な方法、組成物で使用するための植物抽出物、および化粧的ケアの方法
EP2949752B1 (de) 2008-09-22 2017-12-20 RXi Pharmaceuticals Corporation Selbstfreisetzende rnai-verbindungen von reduzierter grösse
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
WO2011133876A2 (en) * 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
EP2814455B1 (de) 2012-02-13 2017-07-19 Unilever N.V. Hautaufhellende zusammensetzung
CN102925443A (zh) * 2012-11-01 2013-02-13 东北师范大学 靶向沉默MyoⅩ的序列制备及其载体的构建
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
CN105560635A (zh) * 2015-09-17 2016-05-11 张名静 一种治疗黑色棘皮病的中药
BR102018001541B1 (pt) 2018-01-24 2021-05-11 Universidade Federal Do Rio Grande Do Sul composição farmacêutica nanométrica na forma de lipossomas ou nanoemulsão que contém sequências específicas de rna de interferência
JP2022541896A (ja) * 2019-07-18 2022-09-28 オリパス コーポレーション メラノフィリンアンチセンスオリゴヌクレオチド
WO2021020412A1 (ja) * 2019-07-30 2021-02-04 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772607B1 (fr) 1997-12-19 2000-02-04 Oreal Utilisation de derives amides d'amino phenol comme agents depigmentants
GB9903216D0 (en) 1999-02-13 1999-04-07 Zylepsis Ltd Preservative compounds,compositions and methods of making and using the same
IL144850A0 (en) 1999-03-22 2002-06-30 Pfizer Resorcinol derivatives
HN2000000033A (es) 1999-03-22 2001-02-02 Pfizer Prod Inc Composicion de resorcinol
FR2804960B1 (fr) 2000-02-11 2005-06-24 Lvmh Rech Nouveaux oligonucleotides et utilisation d'oligonucleotides modulant l'expression de la tyrosinase et de la tyrosinase- related-protein 1 comme agents depigmentants
US7504385B2 (en) * 2003-12-17 2009-03-17 Avon Products, Inc. si-RNA-mediated gene silencing technology to inhibit tyrosinase and reduce pigmentation
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
EP1752536A4 (de) * 2004-05-11 2008-04-16 Alphagen Co Ltd Rna-störung verursachendes polynukleotid sowie verfahren zur regulation der genexpression unter verwendung davon

Also Published As

Publication number Publication date
HRP20100666T1 (hr) 2011-03-31
CA2632837A1 (fr) 2007-06-21
JP2009518022A (ja) 2009-05-07
IL191728A0 (en) 2011-08-01
EP1963507A1 (de) 2008-09-03
US7999096B2 (en) 2011-08-16
AU2006325359A1 (en) 2007-06-21
DK1963507T3 (da) 2011-01-03
ES2351996T3 (es) 2011-02-14
NO20083089L (no) 2008-07-10
TNSN08252A1 (en) 2009-10-30
ZA200805739B (en) 2009-07-29
KR20080079298A (ko) 2008-08-29
FR2894582B1 (fr) 2008-02-22
DE602006017586D1 (de) 2010-11-25
AU2006325359A2 (en) 2008-07-31
CN101326286A (zh) 2008-12-17
FR2894582A1 (fr) 2007-06-15
EP1963507B1 (de) 2010-10-13
PL1963507T3 (pl) 2011-04-29
PT1963507E (pt) 2010-11-24
BRPI0619738A2 (pt) 2011-10-11
RU2008125041A (ru) 2010-01-20
WO2007068704A1 (fr) 2007-06-21
MA30034B1 (fr) 2008-12-01
US20090239934A1 (en) 2009-09-24
EP2264171A1 (de) 2010-12-22

Similar Documents

Publication Publication Date Title
ATE484585T1 (de) Anti-myosin-va-sirna und depigmentierung der haut
ATE546526T1 (de) Hybrid-interferenz-rna
WO2010033247A3 (en) Reduced size self-delivering rnai compounds
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
ATE540118T1 (de) Antisense-verbindungen
AU2008339215A8 (en) Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof
GB0507019D0 (en) RNA interference mediated treatment of polyglutamine (polyq) repeat expansion diseases using short interfering nucleic acid (sina)
MX2012002272A (es) Dominios cataliticos de lisil oxidasa y loxl2.
EP1606304A4 (de) Genexpressionsregulierende nukleotidsequenzen sowie konstrukte und verfahren unter verwendung davon
EP2021507A4 (de) Zusammensetzungen und verfahren zur hemmung der pcsk9-genexpression
WO2006039253A3 (en) Sirna-mediated gene silencing of alpha synuclein
WO2007031319A8 (en) Compositions comprising immunostimulatory rna oligonucleotides and methods for producing said rna oligonucleotides
WO2011056005A3 (ko) 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
ATE528008T1 (de) Rnai-modulation von aha und ihre therapeutische verwendung
WO2006045591A3 (en) Method and constructs for delivering double stranded rna to pest organisms
ATE293688T1 (de) Chimerische antisense-oligonukleotide aus arabinofuranose-analogen und deoxyribose- nukleotide
Richards et al. RNA bandages for photoregulating in vitro protein synthesis
ATE418611T1 (de) Sirna-gesteuerte genexpressionsunterdrückung in transgenetischen tieren
DK1339853T3 (da) Isolerede luciferaser og deres anvendelse
WO2006047635A3 (en) Methods and compositions for seprase inactivation
CO2021015542A2 (es) Molécula oligomérica de ácido nucleico y uso de esta en el tratamiento de la porfiria aguda intermitente
Wang et al. Inhibition of transcription and antiproliferative effects in a cancer cell line using antigene oligonucleotides containing artificial nucleoside analogues
WO2005078090A3 (de) Antisense-oligonukleotide zur behandlung von unerwünschter pigmentierung der haut und der haare
ATE529124T1 (de) Verwendung des engrailed homeodomänen-proteins als anxiolytikum
ATE520775T1 (de) Raygraspollen-spezifische promotoren und expressionskonstrukte

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1963507

Country of ref document: EP